Pfizer is a leader in corporate governance, and good corporate governance is fundamental to Pfizer's business. A cornerstone of governance at Pfizer is our shareholder outreach program, through which we regularly engage with our investors and stakeholders around the world to gain insight into the burgeoning issues at the forefront of their business policies and guidelines. We aim to seek a more collaborative approach to specific issues of importance to us and our industry. Shareholder input helps us to continue to drive innovations in policies and disclosures on corporate political activities and other key governance areas.
Our annually elected board of directors is comprised entirely of independent directors other than our Chairman and CEO, Albert Bourla. Each Director provides a unique business perspective, experience and skills, all valuable to the Company. The board plays a vital oversight role, which fosters shareholder value and affects stakeholder confidence, through discussions with senior leaders and external advisers covering a wide range of matters including strategy, financial performance, compliance, and public policy.
Regulatory reforms have resulted in the transformation of the corporate governance landscape and Pfizer has embraced these amendments, and in some cases has been ahead of the game in adopting innovations that are now requirements. It is essential that we practice responsible business principles, and continue to demonstrate our commitment to excellence to sustain value for our investors and stakeholders.
Pfizer's Board Committees are integral in defining the corporate structure and governance principles. Download the Corporate Governance Principles and meet the current committees.
Board Committees & Charters Board Policies. Pfizer's Board of Directors implement policies to ensure ethical conduct for members of the leadership team. For inquiries, contact our Board of Directors.
Learn more about Pfizer's approach to corporate governance, compliance, responsibility, and more.
For more information on Pfizer policies, products and more, contact any of Pfizer's directors via e-mail.
This webcast may contain forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candidates, strategic reviews, capital allocation, business-development plans, the benefits expected from the reorganization of our commercial operations into three businesses effective at the beginning of our 2019 fiscal year, our acquisitions and other business development activities, our proposed transaction with GSK to combine our respective consumer healthcare businesses into a new consumer healthcare joint venture, our ability to successfully capitalize on growth opportunities or prospects, manufacturing and product supply and plans relating to share repurchases and dividends, among other things, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
A description of these risks and uncertainties can be found in Pfizer’s most recent Annual Report on Form 10-K and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
The forward-looking statements in the webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.
The following transcript contains forward-looking statements about our anticipated future financial performance that involve substantial risks and uncertainties. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek” and other words and terms of similar meaning. Factors that could cause actual results to differ materially from past results and future plans and projected future results are described in our Form 8-K furnished with the U.S. Securities and Exchange Commission on January 12, 2021 and linked here, which also contains information regarding our use of preliminary financial guidance.